Status: Recruiting
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.
Participants needed: 150
Trial details
Phase: Phase 2Age: 30+Biological sex: AllType: InterventionalSponsor: Ann-Sofie BackmanUpdated: Dec 17, 2024Locations: 8
Eligibility criteria
Proven tumor-free (including patients in which the polyps are removed endoscopic... [+3]
Presence of colorectal endoscopically non-removable benign neoplasia (patient ca... [+15]